Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors

被引：0
|
作者：
Hui-Te Hsu
Chu-Chun Yu
Yun-Hsiang Lee
Jui-Chun Chan
Chia-Yu Chu
机构：
[1] Department of Dermatology,School of Nursing
[2] Far Eastern Memorial Hospital,Department of Nursing
[3] National Taiwan University College of Medicine,Department of Nursing
[4] National Taiwan University Hospital,Department of Dermatology
[5] Mackay Medical College,undefined
[6] National Taiwan University Hospital and National Taiwan University College of Medicine,undefined
来源：
Supportive Care in Cancer | 2022年 / 30卷
关键词：
Quality of life; Adverse events; Epidermal growth factor receptor-tyrosine kinase inhibitors; Osimertinib; Lung cancer; Paronychia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9211 / 9219
页数：8
相关论文
共 50 条
  • [21] Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors
    Rosentreter, Jelena
    Alt, Juergen
    Fried, Marius
    Chakupurakal, Geothy
    Stratmann, Jan
    Kraemer, Irene
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1147 - 1158
  • [22] HOW SENSITIVE ARE EPIDERMAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS FOR SQUAMOUS CELL CARCINOMA OF THE LUNG HARBORING EPIDERMAL GROWTH FACTOR RECEPTOR GENE SENSITIVE MUTATIONS?
    Hata, A.
    Katakami, N.
    Kunimasa, K.
    Yoshioka, H.
    Fujita, S.
    Kaji, R.
    Imai, Y.
    Tomii, K.
    Iwasaku, M.
    Nishiyama, A.
    Ishida, T.
    RESPIROLOGY, 2011, 16 : 185 - 185
  • [23] Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance
    Scheffler, Matthias
    Merkelbach-Bruse, Sabine
    Bos, Marc
    Fassunke, Jana
    Gardizi, Masyar
    Michels, Sebastian
    Groneck, Laura
    Schultheis, Anne M.
    Malchers, Florian
    Leenders, Frauke
    Kobe, Carsten
    Koenig, Katharina
    Heukamp, Lukas C.
    Sos, Martin L.
    Thomas, Roman K.
    Buettner, Reinhard
    Wolf, Juergen
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) : E40 - E43
  • [24] Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: A meta-analysis
    Ameratunga, Malaka
    Pavlakis, Nick
    Gebski, Val
    Broad, Adam
    Khasraw, Mustafa
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 273 - 278
  • [25] Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
    Nagano, Tatsuya
    Tachihara, Motoko
    Nishimura, Yoshihiro
    CELLS, 2018, 7 (11)
  • [26] The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases
    Zhou, Jianxi
    Zhou, Yingnan
    Sun, Yunchuan
    Xiao, Li
    Lu, Hongling
    Yin, Xiaoming
    Fan, Kui
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [27] Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation
    Fang, Wenfeng
    Zhang, Jianwei
    Liang, Wenhua
    Huang, Yan
    Yan, Yue
    Wu, Xuan
    Hu, Zhihuang
    Ma, Yuxiang
    Zhao, Hongyun
    Zhao, Yuanyuan
    Yang, Yunpeng
    Xue, Cong
    Zhang, Jing
    Zhang, Li
    JOURNAL OF THORACIC DISEASE, 2013, 5 (05) : 585 - 592
  • [28] Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
    Banno, Eri
    Togashi, Yosuke
    Nakamura, Yu
    Chiba, Masato
    Kobayashi, Yoshihisa
    Hayashi, Hidetoshi
    Terashima, Masato
    de Velasco, Marco A.
    Sakai, Kazuko
    Fujita, Yoshihiko
    Mitsudomi, Tetsuya
    Nishio, Kazuto
    CANCER SCIENCE, 2016, 107 (08) : 1134 - 1140
  • [29] Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis
    Zhang, Xiao-Hang
    Li, Cheng
    Dai, Chen-Fei
    Zhou, Bao-Sen
    THORACIC CANCER, 2011, 2 (03) : 101 - 108
  • [30] Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma
    Qiao, Xiaojuan
    Zhang, Ye
    Wang, Jinghui
    Nong, Jingying
    Li, Xi
    Yang, Xinjie
    Lv, Jialin
    Zhang, Hui
    Qin, Na
    Zhang, Quan
    Yue, Wentao
    Zhang, Shucai
    THORACIC CANCER, 2015, 6 (06) : 678 - 686
12345